Company Information

  

Address: 800 THIRD AVENUE
11TH FLOOR 
City: NEW YORK 
State: NY 
Zip Code: 10022 
Telephone: (212) 682-8452 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical stage pharmaceutical company developing novel therapies for ophthalmic diseases. Our lead clinical asset, topical Squalamine (also known as squalamine lactate ophthalmic solution, 0.2%, or OHR-102), is a novel therapeutic product which could provide a non-invasive therapy to improve vision outcomes beyond that achieved with current standard of care. We are evaluating Squalamine in combination with Lucentis┬« injections for the treatment of wet-AMD. This is based on the data from a Phase 2 clinical trial in wet-AMD where a positive and clinically meaningful vision benefit was seen with Squalamine combination therapy in classic containing choroidal neovascularization (classic CNV) as well as those subjects with occult neovascularization (occult CNV) less than 10mm2. We also have a sustained release platform technology which we acquired in May 2014.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-0.21NAN/E
12/2017-0.39NAN/E
09/2017-0.53NAN/E
06/2017-0.66NAN/E
03/2017-0.88NAN/E
12/2016-0.83NAN/E
09/2016-0.82NAN/E
06/2016-0.74NAN/E

Key Financial Ratios and Statistics

FYE: 09/30

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.18Total Liab/Total Assets0.18
Net Inc/Total Assets-0.85Total Liab/Inv Cap0.22
Net Inc/Inv Cap-1.04Total Liab/Comm Equity0.04
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/Equity0.00
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio2.64
Inventory TurnoverNACurrent Ratio2.64
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps -0.64 1.51 0.72 1.33
Operating Income -2.18 -4.18 -5.26 -3.86
Interest Exp NA NA NA NA
Pretax Income -2.18 -4.15 -5.24 -3.90
Other Income -0.05 0.03 -0.01 0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -2.18 -4.15 -5.24 -3.90

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 5.22 8.72 12.80 18.08
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 5.84 8.82 13.02 18.52
Net Property, Plant & Equipment 0.02 0.06 0.06 0.08
Total Assets 19.39 23.43 27.93 33.72
Liabilities        
Accounts Payable 1.44 3.60 4.83 5.44
Debt in Current Liabilities 0.29 0.00 0.11 0.16
Total Current Liabilities 1.73 3.60 4.93 5.59
Long-Term Debt NA NA NA NA
Total Liabilities 1.73 3.75 5.08 5.74
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -114.42 -112.24 -108.09 -102.84
Treasury Stock NA NA NA NA
Total Stockholders' Equity 17.66 19.68 22.84 27.97
Total Liabilities and Stockholders' Equity 19.39 23.43 27.93 33.72

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -3.52 -4.20 -5.27 -4.12
Net Cash Provided by Investing Activities 0.00 0.00 0.01 0.09
Net Cash Provided by Financing Activities 0.01 0.12 -0.01 12.59

Annual Summary Data (Millions)

Year Sales Net Income EPS
09/20130.00-5.65-0.30
09/20140.00-9.13-0.41
09/20150.00-15.20-0.54
09/20160.00-25.77-0.82
09/20170.00-23.81-0.53
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/18505,1699.16




Report Date : 6/18/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.